RESUMEN
Over one hundred clinical trials since 2005 have failed to significantly improve the prognosis of glioblastoma. Since 2005, the standard of care has been maximal resection followed by 60Gy irradiation over six weeks with daily temozolomide. With this, a median survival of 2 years can be expected. This short paper reviewed how the pharmacodynamic attributes of an EMA/FDA approved, cheap, generic drug to treat pain, celecoxib, intersect with pathophysiological elements driving glioblastoma growth, such that growth drive inhibition can be expected from celecoxib. The two main attributes of celecoxib are carbonic anhydrase inhibition and cyclooxygenase-2 inhibition. Both attributes individually have been in active study as adjuncts during current cancer treatment, including that of glioblastoma. That research is briefly reviewed here. This paper concludes from the collected data, that starting celecoxib, 600 to 800mg twice daily before surgery and continuing it through the chemoirradiation phase of treatment would be a low-risk intervention with sound rationale.
Asunto(s)
Glioblastoma , Celecoxib/uso terapéutico , Ciclooxigenasa 2 , Glioblastoma/tratamiento farmacológico , Glioblastoma/radioterapia , Humanos , Temozolomida/uso terapéuticoRESUMEN
This paper presents a short review of data supporting a dexamethasone sparing regimen, SEC, to reduce glioblastoma related brain edema. The conclusion of the reviewed data is that the rationale and risk/benefit ratio favors a pilot study to determine if the three drug regimen of SEC can reduce need for corticosteroid use during the course of glioblastoma. Details of how selected pathophysiological aspects of brain edema occurring during the course of glioblastoma and its treatment intersect with the established action of the three old drugs of SEC indicate that they can be repurposed to reduce that edema. Current first-line treatment of this edema is dexamethasone or related corticosteroids. There are multiple negative prognostic implications of both the edema itself and of dexamethasone, prime among them shortened survival, making a dexamethasone sparing regimen highly desirable. SEC uses spironolactone, an antihypertensive potassium-sparing diuretic acting by mineralocorticoid receptor inhibition, ecallantide acting to inhibit kallikrein activation marketed to treat hereditary angioedema, and clotrimazole, an old antifungal drug that inhibits intermediate conductance Ca++ activated K+ channel (KCa3.1). These three old drugs are well known to most clinicians, have a well-tolerated safety history, and have a robust preclinical database showing their potential to reduce the specific edema of glioblastoma. Additionally, these three drugs were chosen by virtue of each having preclinical evidence of glioblastoma growth and/or migration inhibition independent of their edema reduction action. A clinical study of SEC is being planned.
Asunto(s)
Clotrimazol , Glioblastoma , Clotrimazol/uso terapéutico , Dexametasona , Glioblastoma/tratamiento farmacológico , Humanos , Péptidos , Proyectos Piloto , Espironolactona/uso terapéuticoRESUMEN
Multiple pharmacological interventions tested over the last decades have failed to reduce ARDS mortality. This short note recounts past data indicating that (i) neutrophils home along an IL-8 gradient, (ii) in ARDS, massive neutrophil accumulation and degranulation in and along bronchoalveolar spaces contributes to damage and hypoxia, (iii) large increases in IL-8 are one of the chemotaxic signals drawing neutrophils to the ARDS lung, and (iv) old data from dermatology and glioblastoma research showed that the old drug against Hansen's disease, dapsone, inhibits neutrophils' chemotaxis to IL-8. Therefore dapsone might lower neutrophils' contributions to ARDS lung pathology. Dapsone can create methemoglobinemia that although rarely problematic it would be particularly undesirable in ARDS. The common antacid drug cimetidine lowers risk of dapsone related methemoglobinemia and should be given concomitantly.
Asunto(s)
Antiinfecciosos/uso terapéutico , Dapsona/uso terapéutico , Neutrófilos/efectos de los fármacos , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Antiinfecciosos/farmacología , Cimetidina/uso terapéutico , Dapsona/farmacología , Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Humanos , Metahemoglobinemia/inducido químicamente , Metahemoglobinemia/prevención & controlRESUMEN
We have previously reported that combined inhibition of the epidermal growth factor receptor by erlotinib and of RAC1 by NSC23766 yielded a synergistic antiproliferative effect on established and primary cultured glioblastoma cells. The current study aimed at identifying the molecular mechanism. Staining for annexin V/PI or carboxyfluorescein succinimidyl ester was performed in order to determine the induction of apoptosis, necrosis or cytostasis in established and primary cultured glioblastoma cells. Moreover, expression of Ki-67 was determined by immunofluorescence, and the expression of cell cycle proteins was analysed by Western blot. Our data show that combined treatment with erlotinib and NSC23766 resulted in a reduced number of cell divisions, a significantly decreased Ki-67 expression, increased apoptosis and autophagy when compared to single agent treatments. On the molecular level, concomitant treatment with both agents resulted in a pronounced downregulation of cyclin D1, cyclin-dependent kinases 2, 4 and 6, as well as of survivin when compared to treatments with either agent alone. In conclusion, we demonstrate that combined treatment of human glioma cell lines in vitro with erlotinib and NSC23766 markedly inhibits cell division, induces apoptosis independent of caspase-3 activation and induces autophagy concomitant with suppression of survivin.
Asunto(s)
Citostáticos/administración & dosificación , Receptores ErbB/metabolismo , Glioma/metabolismo , Proteínas Inhibidoras de la Apoptosis/metabolismo , Transducción de Señal/fisiología , Proteína de Unión al GTP rac1/metabolismo , Aminoquinolinas/administración & dosificación , Aminoquinolinas/toxicidad , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidad , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Línea Celular Tumoral , Citostáticos/toxicidad , Receptores ErbB/antagonistas & inhibidores , Clorhidrato de Erlotinib/administración & dosificación , Clorhidrato de Erlotinib/toxicidad , Humanos , Proteínas Inhibidoras de la Apoptosis/antagonistas & inhibidores , Pirimidinas/administración & dosificación , Pirimidinas/toxicidad , Transducción de Señal/efectos de los fármacos , Survivin , Proteína de Unión al GTP rac1/antagonistas & inhibidoresRESUMEN
BACKGROUND: The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib has failed in many ways to be as potent in the anti-cancer role as pre-clinical studies would have suggested. This paper traces some aspects of this failure to a compensatory erlotinib-mediated increase in interleukin-8. Many other-but not all- cancer chemotherapeutic cytotoxic drugs also provoke a compensatory increase in a malignant clone's interleukin-8 synthesis. Untreated glioblastoma and other cancer cells themselves natively synthesize interleukin-8. Interleukin-8 has tumor growth promoting, mobility and metastasis formation enhancing, effects as well as pro-angiogenesis effects. FINDINGS: The old sulfone antibiotic dapsone- one of the very first antibiotics in clinical use- has demonstrated several interleukin-8 system inhibiting actions. Review of these indicates dapsone has potential to augment erlotinib effectiveness. Erlotinib typically gives a rash that has recently been proven to come about via an erlotinib triggered up-regulated keratinocyte interleukin-8 synthesis. The erlotinib rash shares histological features reminiscent of typical neutrophilic dermatoses. Dapsone has an established therapeutic role in current treatment of other neutrophilic dermatoses. CONCLUSION: Thus, dapsone has potential to both improve the quality of life in erlotinib treated patients by amelioration of rash as well as to short-circuit a growth-enhancing aspect of erlotinib when used in the anti-cancer role.
RESUMEN
We present here a potential new treatment adjunct for glioblastoma. Building on murine studies, a series of papers appeared recently showing that therapeutic irradiation of the ipsilateral subventricular zone (SVZ) retards growth of more peripherally growing cortical glioblastomas in humans, suggesting a tumor trophic function for the SVZ. Further studies showed that SVZ cells migrate out towards a peripheral glioblastoma. Dopamine signaling through D3 subtype receptor indirectly drives this centrifugal migration in humans. Since psychiatry has several drugs with good D3 blocking attributes, such as fluphenazine, or perphenazine, we suggest that adding one of these D3 blocking drugs to current standard treatment of resection followed by temozolomide and irradiation might prolong survival by depriving glioblastoma of the trophic functions previously subserved by dopaminergic signaling on SVZ cells.
Asunto(s)
Neoplasias Encefálicas/tratamiento farmacológico , Ventrículos Cerebrales/patología , Antagonistas de Dopamina/uso terapéutico , Glioblastoma/tratamiento farmacológico , Células Madre Neoplásicas/efectos de los fármacos , Perfenazina/uso terapéutico , Ventrículos Cerebrales/efectos de los fármacos , Antagonistas de Dopamina/farmacología , Humanos , Perfenazina/farmacologíaRESUMEN
The concept of a stem cell subpopulation as understood from normal epithelial tissue or bone marrow function has been extended to our understanding of cancer tissue and is now the target of treatment efforts specifically directed to this subpopulation. In glioblastoma, as well as in other cancers, increased expression of aldehyde dehydrogenase (ALDH) has been found localized within a minority sub-population of tumor cells which demonstrate stem cell properties. A separate body of research associated increased expression of heat-shock protein-90 (HSP90) with stem cell attributes. We present here results from our initial immunohistochemistry study of human glioblastoma biopsy tissue where both ALDH and HSP90 tended to be co-expressed in high amounts in the same minority of cells. Since 12% of all cells in the six biopsies studied were ALDH positive and 17% were HSP90 positive, by chance alone 2% would have been expected to be positive for both. In fact 7% of all cells simultaneously expressed both markers-a significant difference (p = 0.037). That two previously identified proteins associated with stem cell attributes tend to be co-expressed in the same individual glioblastoma cells might have clinical utility. Disulfiram, used to treat alcoholism for half-a century now, is a potent ALDH inhibitor and the old anti-viral drug ritonavir inhibits HSP90. These should be explored for the potential to retard aspects of glioblastoma stem cells' function subserved by ALDH and HSP90.
Asunto(s)
Aldehído Deshidrogenasa/metabolismo , Glioblastoma/patología , Proteínas HSP90 de Choque Térmico/metabolismo , Regulación Neoplásica de la Expresión Génica , Glioblastoma/enzimología , Glioblastoma/metabolismo , Humanos , Transporte de ProteínasRESUMEN
BACKGROUND: Despite standard dual antiplatelet therapy (DAT) (acetylsalicylic acid [ASA] and clopidogrel), there is a ≥ 1.4% incidence of in-stent thrombosis in patients with acute coronary syndrome. Factor Xa inhibitors are being investigated for secondary prevention after acute coronary syndrome. OBJECTIVE: To study the antithrombotic effects of the FXa inhibitor rivaroxaban alone or in combination with DAT. METHODS: Bare metal stents (12 per animal, three per intervention period) were deployed in a porcine ex vivo arteriovenous shunt and exposed to flowing arterial blood (shear rate: 1500 s(-1)). In-stent thrombus formation was analyzed under different treatments: vehicle (n = 7 animals); intravenous (i.v.) rivaroxaban (0.11, 0.33, and 1.0 µg kg(-1) min(-1)) (n = 8); rivaroxaban + ASA (1.0 mg kg(-1) i.v.) (n = 6); rivaroxaban + ASA (1.0 mg kg(-1) i.v.) + clopidogrel (0.5 mg kg(-1) i.v.) (n = 7); and ASA (1.0 mg kg(-1) i.v.) + clopidogrel (0.5 mg kg(-1) i.v.) (n = 6). RESULTS: Rivaroxaban dose-dependently reduced stent thrombus weight by ≤ 66% vs. vehicle (P < 0.05, all doses). Rivaroxaban + ASA further reduced thrombus weight vs. vehicle (86% at the highest rivaroxaban dose; P < 0.001). DAT reduced thrombus weight by ≤ 79%. However, rivaroxaban + ASA + clopidogrel almost completely abolished in-stent thrombus formation (98% reduction vs. vehicle at the highest rivaroxaban dose; P < 0.001). CONCLUSIONS: Our data on the inhibitory effect of rivaroxaban alone or with DAT are consistent with the ATLAS 2 trial findings, and support its potential use for preventing stent thrombosis after stent deployment.
Asunto(s)
Aspirina/uso terapéutico , Morfolinas/uso terapéutico , Stents/efectos adversos , Tiofenos/uso terapéutico , Trombosis/tratamiento farmacológico , Ticlopidina/análogos & derivados , Animales , Aspirina/administración & dosificación , Clopidogrel , Quimioterapia Combinada , Femenino , Morfolinas/administración & dosificación , Agregación Plaquetaria , Rivaroxabán , Porcinos , Porcinos Enanos , Tiofenos/administración & dosificación , Trombosis/etiología , Ticlopidina/administración & dosificación , Ticlopidina/uso terapéuticoRESUMEN
Lopez-Gomez et al. recently published remarkable but mechanistically unexplained empirical evidence that the old antibiotic dapsone has antiepileptic activity. We addressed the question "Why should a sulfone antibiotic reduce seizures?". We report here our conclusions based on data from past studies that seizures are associated with elevated interleukin-8 (IL-8) and that dapsone inhibits IL-8 release and function in several different clinical and experimental contexts. Diverse CNS insults cause an increase in CNS IL-8. Thus, the pro-inflammatory environment generated by increase IL-8 leads to a lower seizure threshold. Together this evidence indicates dapsone exerts anti-seizure activity by diminishing IL-8 signalling. Since IL-8 is clearly upregulated in glioblastoma and contributes to the florid angiogenesis of that disease, and since interference with IL-8 function has been shown to inhibit glioblastoma invasion and growth in several experimental models, and dapsone has been repeatedly been shown to clinically inhibit IL-8 function when used to treat human neutrophilic dermatoses, we believe that dapsone thereby reduces seizures by countering IL-8 function and may similarly retard glioblastoma growth by such anti-IL-8 function.
Asunto(s)
Dapsona/farmacología , Dapsona/uso terapéutico , Sistemas de Liberación de Medicamentos/métodos , Glioblastoma/tratamiento farmacológico , Glioblastoma/patología , Neutrófilos/efectos de los fármacos , Neutrófilos/metabolismo , Convulsiones/tratamiento farmacológico , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antiinfecciosos/uso terapéutico , Humanos , Factores de Crecimiento Endotelial Vascular/efectos de los fármacos , Factores de Crecimiento Endotelial Vascular/uso terapéuticoRESUMEN
An acute subdural hematoma (ASDH) induces pathomechanisms which worsen outcome after traumatic brain injury, even after a small hemorrhage. Synergistic effects of a small ASDH on brain damage are poorly understood, and were studied here using neuromonitoring for 10 h in an injury model of controlled cortical impact (CCI) and ASDH. Pigs (n = 32) were assigned to 4 groups: sham, CCI (2.5 m/s), ASDH (2 ml) and CCI + ASDH. Intracranial pressure was significantly increased above sham levels by all injuries with no difference between groups. CCI and ASDH reduced ptiO(2) by a maximum of 36 ± 9 and 26 ± 11%, respectively. The combination caused a 31 ± 11% drop. ASDH alone and in combination with CCI caused a significant elevation in extracellular glutamate, which remained increased longer for CCI + ASDH. The same two groups had significantly higher peak lactate levels compared to sham. Somatosensory evoked potential (SSEP) amplitude was persistently reduced by combined injury. These effects translated into significantly elevated brain water content and histological damage in all injury groups. Thus, combined injury had stronger effects on glutamate and SSEP when compared to CCI and ASDH, but no clear-cut synergistic effects of 2 ml ASDH on trauma were observed. We speculate that this was partially due to the CCI injury severity.
Asunto(s)
Lesiones Encefálicas/complicaciones , Hematoma Subdural Agudo/etiología , Animales , Edema Encefálico/etiología , Edema Encefálico/patología , Edema Encefálico/fisiopatología , Lesiones Encefálicas/patología , Lesiones Encefálicas/fisiopatología , Circulación Cerebrovascular , Modelos Animales de Enfermedad , Potenciales Evocados Somatosensoriales , Ácido Glutámico/metabolismo , Hematoma Subdural Agudo/patología , Hematoma Subdural Agudo/fisiopatología , Presión Intracraneal , Ácido Láctico/metabolismo , Masculino , Monitoreo Fisiológico , Sus scrofaRESUMEN
As current treatments for glioblastoma commonly fail to cure, the need for more effective therapeutic options is overwhelming. Here, we summarize experimental evidence in support of the suggestion that metformin and olanzepine have potential to enhance the cytotoxic effects of temozolomide, an alkylating chemotherapeutic agent commonly used to treat glioblastoma. Although the primary path leading to temozolomide-induced cell death is formation of O-6-methylguanine and apoptotic signalling triggered by O-6-methyl G:T mispairs, that apoptotic signalling goes through a step mediated by AMP-activated protein kinase (AMPK). Metformin or olanzapine have been shown independently to enhance AMPK activation. Metformin to treat diabetes and olanzapine to treat psychiatric disorders are well tolerated and have been used clinically for many years. Thus it should be feasible to increase AMPK activation and add to the pro-apoptotic effects of temozolomide, by adding metformin and olanzapine to the therapeutic regimen. Clinical assessment of the potential benefit of such combined therapy against glioblastoma is warranted.
Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Antineoplásicos Alquilantes/uso terapéutico , Benzodiazepinas/farmacología , Dacarbazina/análogos & derivados , Metformina/farmacología , Animales , Antineoplásicos Alquilantes/administración & dosificación , Apoptosis/efectos de los fármacos , Benzodiazepinas/administración & dosificación , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/enzimología , Neoplasias Encefálicas/patología , Línea Celular Tumoral , Dacarbazina/administración & dosificación , Dacarbazina/uso terapéutico , Metabolismo Energético/efectos de los fármacos , Activación Enzimática/efectos de los fármacos , Glioblastoma/tratamiento farmacológico , Glioblastoma/enzimología , Glioblastoma/patología , Humanos , Metformina/administración & dosificación , Olanzapina , TemozolomidaRESUMEN
WHAT IS KNOWN AND BACKGROUND: Two receptor signaling pathways that are commonly active in facilitating glioblastoma growth and invasion- that of CCR5 and neurokinin (NK)-1R- have small molecule inhibitors that are FDA approved and marketed to treat other conditions. The anti-HIV drug, maraviroc, inhibits human CCR5's ligand from binding, and hence blocks CCR5 stimulation. The anti-nausea drug aprepitant blocks substance P signaling at NK-1R. AIMS AND OBJECTIVE: We propose on the basis of molecular insights that a combination of the two drugs is likely to be useful in the treatment of glioblastoma. COMMENT: After stimulation by their respective ligands both CCR5 and NK-1R, through intermediaries, phosphorylate and thereby activate ERK1/2, triggering in turn migratory and mitotic events. Neurokinin-1R second messenger signaling also happens to serine phosphorylate CCR5. Phosphorylated CCR5 exhibits amplified activity after agonist ligation. Therefore, aprepitant and maraviroc combined treatment is expected to exert synergestic inhibition of growth enhancing signaling in glioblastoma. Inhibiting an amplifier is equivalent to amplifying an inhibitor. Since the two suggested drugs are non-cytotoxic they are envisioned as adjunctive treatments to current standard temozolomide, radiation, and bevacizumab, all to be used after debulking primary resection. WHAT IS NEW AND CONCLUSION: Our analysis makes the case for a well-designed trial of the proposed combination in the treatment of glioblastoma.
Asunto(s)
Antineoplásicos/uso terapéutico , Antagonistas de los Receptores CCR5 , Ciclohexanos/uso terapéutico , Glioblastoma/tratamiento farmacológico , Morfolinas/uso terapéutico , Antagonistas del Receptor de Neuroquinina-1 , Triazoles/uso terapéutico , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/farmacología , Fármacos Anti-VIH/uso terapéutico , Antieméticos/efectos adversos , Antieméticos/farmacología , Antieméticos/uso terapéutico , Antineoplásicos/efectos adversos , Antineoplásicos/farmacología , Aprepitant , Ciclohexanos/efectos adversos , Ciclohexanos/farmacología , Aprobación de Drogas , Interacciones Farmacológicas , Glioblastoma/metabolismo , Humanos , Maraviroc , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Morfolinas/efectos adversos , Morfolinas/farmacología , Fosforilación/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Triazoles/efectos adversos , Triazoles/farmacología , Estados Unidos , United States Food and Drug AdministrationRESUMEN
Glioblastoma treatment as now constituted offers increased survival measured in months over untreated patients. Because glioblastomas are active in synthesizing a bewildering variety of growth factors, a systematic approach to inhibiting these is being undertaken as treatment adjunct. The serotonin 7 receptor is commonly overexpressed in glioblastoma. Research documentation showing agonists at serotonin receptor 7 cause increased extracellular regulated kinase 1/2 activation, increased interleukin-6 synthesis, increased signal transducer and activator of transcription-3 activation, increased resistance to apoptosis and other growth enhancing changes in glioblastoma is reviewed in this paper. Because three drugs in wide use to treat thought disorders - paliperidone, pimozide and risperidone - are also potent and well-tolerated inhibitors at serotonin receptor 7, these drugs should be studied for growth factor deprivation in an adjunctive role in glioblastoma treatment.
Asunto(s)
Antipsicóticos/uso terapéutico , Glioblastoma/tratamiento farmacológico , Receptores de Serotonina/efectos de los fármacos , Antagonistas de la Serotonina/uso terapéutico , Antipsicóticos/farmacología , Quimioterapia Adyuvante , Glioblastoma/metabolismo , Humanos , Interleucina-6/metabolismo , Modelos Biológicos , Receptores de Serotonina/metabolismo , Antagonistas de la Serotonina/farmacología , Transducción de Señal/efectos de los fármacosAsunto(s)
Sistema Nervioso Central/inmunología , Sistemas de Liberación de Medicamentos/normas , Piperazinas/administración & dosificación , Pirimidinas/administración & dosificación , Animales , Benzamidas , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/inmunología , Sistema Nervioso Central/efectos de los fármacos , Sistema Nervioso Central/patología , Humanos , Mesilato de Imatinib , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Leucemia Mielógena Crónica BCR-ABL Positiva/inmunología , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Metanfetamina/administración & dosificaciónRESUMEN
An accumulating body of evidence incriminates Rho kinase (ROCK) in the pathogenesis of pulmonary hypertension (PH). The therapeutic efficacy of azaindole-1, a novel highly selective and orally active ROCK inhibitor, has not yet been investigated in PH. This study aimed to investigate the effects of azaindole-1 on 1) acute hypoxic pulmonary vasoconstriction (HPV), 2) proliferation of pulmonary arterial smooth muscle cells (PASMCs) and 3) animal models of PH. Azaindole-1 significantly inhibited HPV in isolated, ventilated and buffer-perfused murine lungs and proliferation of primary rat PASMCs in vitro. Azaindole-1 was administered orally from 21 to 35 days after monocrotaline (MCT) injection in rats and hypoxic exposure in mice. Azaindole-1 (10 and 30 mg per kg body weight per day in rats and mice, respectively) significantly improved haemodynamics and right ventricular hypertrophy. Moreover, the medial wall thickness and muscularisation of peripheral pulmonary arteries were ameliorated. Azaindole-1 treatment resulted in a decreased immunoreactivity for phospho-myosin phosphatase target subunit 1 and proliferating cell nuclear antigen in pulmonary vessels of MCT-injected rats, suggesting an impaired ROCK activity and reduced proliferating cells. Azaindole-1 provided therapeutic benefit in experimental PH, and this may be attributable to its potent vasorelaxant and antiproliferative effects. Azaindole-1 may offer a useful approach for treatment of PH.
Asunto(s)
Compuestos de Azabiciclo/uso terapéutico , Hipertensión Pulmonar/tratamiento farmacológico , Indoles/uso terapéutico , Animales , Proliferación Celular , Modelos Animales de Enfermedad , Inhibidores Enzimáticos/farmacología , Hemodinámica , Pulmón/patología , Masculino , Ratones , Ratas , Ratas Sprague-Dawley , Telemetría/métodos , Sales de Tetrazolio/farmacología , Tiazoles/farmacología , Timidina/química , Resultado del Tratamiento , Quinasas Asociadas a rho/antagonistas & inhibidoresRESUMEN
BACKGROUND AND PURPOSE: Cysteinyl leukotrienes (CysLTs) have been implicated in the pathophysiology of inflammatory and cardiovascular disorders. Their actions are mediated by CysLT(1) and CysLT(2) receptors. Here we report the discovery of 3-({[(1S,3S)-3-carboxycyclohexyl]amino}carbonyl)-4-(3-{4-[4-(cyclo-hexyloxy)butoxy]phenyl}propoxy) benzoic acid (HAMI3379), the first potent and selective CysLT(2) receptor antagonist. EXPERIMENTAL APPROACH: Pharmacological characterization of HAMI3379 was performed using stably transfected CysLT(1) and CysLT(2) receptor cell lines, and isolated, Langendorff-perfused, guinea pig hearts. KEY RESULTS: In a CysLT(2) receptor reporter cell line, HAMI3379 antagonized leukotriene D(4)- (LTD(4)-) and leukotriene C(4)- (LTC(4)-) induced intracellular calcium mobilization with IC(50) values of 3.8 nM and 4.4 nM respectively. In contrast, HAMI3379 exhibited very low potency on a recombinant CysLT(1) receptor cell line (IC(50) > 10 000 nM). In addition, HAMI3379 did not exhibit any agonistic activity on both CysLT receptor cell lines. In binding studies using membranes from the CysLT(2) and CysLT(1) receptor cell lines, HAMI3379 inhibited [(3)H]-LTD(4) binding with IC(50) values of 38 nM and >10 000 nM respectively. In isolated Langendorff-perfused guinea pig hearts HAMI3379 concentration-dependently inhibited and reversed the LTC(4)-induced perfusion pressure increase and contractility decrease. The selective CysLT(1) receptor antagonist zafirlukast was found to be inactive in this experimental setting. CONCLUSIONS AND IMPLICATIONS: HAMI3379 was identified as a potent and selective CysLT(2) receptor antagonist, which was devoid of CysLT receptor agonism. Using this compound, we showed that the cardiac effects of CysLTs are predominantly mediated by the CysLT(2) receptor.
Asunto(s)
Ácidos Ciclohexanocarboxílicos/farmacología , Antagonistas de Leucotrieno/farmacología , Ácidos Ftálicos/farmacología , Receptores de Leucotrienos/efectos de los fármacos , Animales , Células CHO , Calcio/metabolismo , Línea Celular , Cricetinae , Cricetulus , Ácidos Ciclohexanocarboxílicos/administración & dosificación , Relación Dosis-Respuesta a Droga , Cobayas , Corazón/efectos de los fármacos , Humanos , Indoles , Concentración 50 Inhibidora , Antagonistas de Leucotrieno/administración & dosificación , Leucotrieno C4/metabolismo , Leucotrieno D4/metabolismo , Masculino , Contracción Miocárdica/efectos de los fármacos , Fenilcarbamatos , Ácidos Ftálicos/administración & dosificación , Unión Proteica , Receptores de Leucotrienos/metabolismo , Sulfonamidas , Compuestos de Tosilo/farmacologíaAsunto(s)
Antirreumáticos/farmacología , Antirreumáticos/uso terapéutico , Auranofina/farmacología , Auranofina/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Catepsina B/antagonistas & inhibidores , Glioblastoma/tratamiento farmacológico , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/patología , Catepsina B/metabolismo , Glioblastoma/metabolismo , Glioblastoma/patología , Humanos , Invasividad Neoplásica , Vitamina B 6/metabolismoRESUMEN
This article analyzes the consequences for risk distribution of the French Flood Prevention Action Programme (PAPI). By redirecting floods from the most vulnerable to the least vulnerable areas, PAPIs expose farmers to greater flood risks. This has led local water management institutions to introduce compensation payments. The article outlines the results of an exhaustive survey of all PAPIs in France, which examined the way the compensation policies are set up locally. Results of the survey showed that the proposed policies may be financially non-viable. Several more viable risk-sharing solutions are then discussed, involving insurance schemes, state intervention and local institutions.
Asunto(s)
Inundaciones , Recolección de Datos , Ambiente , Francia , Medición de RiesgoRESUMEN
The 21 amino acid signaling peptide endothelin-1 is commonly elevated in epithelial ovarian cancer, and it mediates or facilitates much of this cancer's aggressive behavior. Ambrisentan (Letairis; Gilead Sciences Inc.) is an antagonist of endothelin-1 at its cognate receptor that has just been approved to treat pulmonary hypertension. Ambrisentan is a well-tolerated pill taken once daily. In theory, it should retard and inhibit lodgement and establishment of disseminated peritoneal micrometastases after debulking surgery.
Asunto(s)
Antineoplásicos/uso terapéutico , Endotelina-1/antagonistas & inhibidores , Neoplasias Glandulares y Epiteliales/tratamiento farmacológico , Neoplasias Ováricas/tratamiento farmacológico , Fenilpropionatos/uso terapéutico , Piridazinas/uso terapéutico , Secuencia de Aminoácidos , Animales , Quimioterapia Adyuvante/métodos , Endotelina-1/química , Femenino , Procedimientos Quirúrgicos Ginecológicos , Humanos , Datos de Secuencia Molecular , Neoplasias Glandulares y Epiteliales/cirugía , Neoplasias Ováricas/cirugíaRESUMEN
Methylnaltrexone (MNTX) was recently FDA approved to treat opiate induced constipation. It happens to also indirectly reduce Src activity. Src is a 54 kDa tyrosine kinase, crucial in signaling of, and link between, vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). Glioblastomas use both EGF and VEGF signaling to enhance growth and neo-angiogenesis. Stem cell sub-fractions of glioblastomas are enriched for high VEGF synthesizing cells so this is a particularly valuable adjunctive target during cytotoxic treatment with drugs like temozolomide. MNTX does not cross the blood-brain barrier (BBB). Methamphetamine (MA) temporarily opens the BBB and therefore may allow methylnaltrexone entry into glioblastoma tissue. MA is FDA approved, marketed to treat attention problems in children. MA-MNTX combination should be tested as glioblastoma treatment adjunct. Temozolomide CSF levels are 10-20% of blood levels. Thus MA may also allow greater brain tissue temozolomide levels yet with lower systemic exposure.